CAMBRIDGE, Mass.--(BUSINESS WIRE)--Surface Oncology, Inc. (Surface), a leader in the development of next-generation cancer immunotherapies, announced today the appointment of Vito J. Palombella, PhD, as Chief Scientific Officer. Dr. Palombella brings twenty years of scientific leadership and experience advancing first-in-class therapeutic programs, and a successful track record of building drug discovery and development organizations.